ALK-Abelló A/S (AKABY)
ALK-Abelló A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Horsholm, DK. The stock last traded at $90.00, up 0.00% on the session, giving a market capitalisation of $0. On trailing twelve-month figures it carries a trailing P/E of 38.51, a net margin of 19.5%. Its beta of 0.43 implies it has historically moved less than the broad market.
ALK-Abelló A/S operates as a global leader in allergy solutions, serving markets across Europe, North America, and internationally. The company provides a diverse range of allergy immunotherapy (AIT) products, offered as injections, sublingual drops, and tablets, specifically formulated to address common allergies like house dust mite, grass, tree pollen, ragweed, and Japanese cedar. In addition to these therapeutic options, ALK-Abelló manufactures adrenaline auto-injectors for emergency treatment of severe allergic reactions and produces diagnostic tools for allergy identification. Prominent products for allergic rhinitis include GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX. ACARIZAX, another key offering, targets both allergic rhinitis and allergic asthma. Established in 1923, ALK-Abelló A/S is headquartered in Hørsholm, Denmark.
ALK-Abelló A/S is most often compared with the following Healthcare names: